The First Affiliated Hospital Of Xiamen University

This study tests whether giving a bone marrow-protecting drug (trilaciclib) before chemotherapy (sacituzumab tirumotecan) can reduce serious side effects like low white blood cell counts in people with advanced EGFR-mutant lung cancer that stopped responding to prior treatments. …

This study tests an oral medication called tofacitinib for people with moderate-to-severe thyroid eye disease who did not get better with or could not tolerate steroids. The drug works by blocking inflammation pathways. Eight participants will take tofacitinib twice daily for 24 …

This early-stage trial tests a new treatment called GB5005 for adults with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and…

This study tests a combination of three drugs (venetoclax, chidamide, and azacitidine) in 30 adults whose acute myeloid leukemia has returned or not responded to standard treatment. The goal is to see if this mix can safely help more patients achieve remission. Participants must …

This study aims to see if a new type of PET scan (68Ga-XACP3) can find prostate cancer tumors as well as or better than the current standard scan (68Ga-PSMA). About 60 adults with newly diagnosed, suspected recurrent, or treated prostate cancer will receive both scans. The result…

This study tests a new type of PET scan (68Ga-NK224) to measure PD-L1 levels in tumors. PD-L1 is a protein that helps some cancers hide from the immune system. The goal is to see if the scan can give the same information as a tissue biopsy, but without the need for surgery. The s…

This study tests a special PET scan that targets a protein called DLL3, found on some neuroendocrine cancer cells. The goal is to see if this scan can find tumors more accurately than current imaging methods. About 60 adults with suspected or confirmed neuroendocrine cancer will …

This study is testing whether a special PET scan can predict how well a targeted cancer drug works in people with advanced lung cancer. About 50 adults with metastatic non-small cell lung cancer will get the scan before and during treatment. The goal is to see if changes in the s…